DALLAS, Jan. 25, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Aastrom Biosciences Inc. (Nasdaq:ASTM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/ASTM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Aastrom Biosciences Inc. (ASTM) is a regenerative medicine company focused on the clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on its Tissue Repair Cell (TRC) technology. The Company's preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations and are investigated for their ability to aid in the regeneration of tissues, such as cardiac, vascular and bone.
Message Board Search for ASTM: http://www.boardcentral.com/boards/ASTM
In the report, the analyst notes:
"Net loss for the quarter ended September 30, 2009, was $3,801,000, or $0.02 per common share compared to $3,913,000, or $0.03 per common share, for the same period in fiscal year 2009. The changes in net loss is primarily the result of fluctuations in spending of research and development expenses, and in part on a per share basis by an increase in the weighted average number of common shares outstanding.
"ASTM recently announced the closing of its previously announced underwritten public offering from which the Company received approximately $12.4 million in net proceeds from the sale of the units (including the partially exercised option of the over-allotment), after underwriting discounts and commissions and other offering expenses. The offering included the sale of 52,077,100 units in total (46,154,000 units from the public offering plus 5,923,100 units exercised-to-date from the over-allotment option) at a public offering price of $0.26 per unit. Oppenheimer & Co. Inc. acted as the sole underwriter for the offering."
To read the entire report visit: http://www.investorsoup.com/lp/ASTM
See what investors say about ASTM at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.